Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7166313 | 0.93 | GAA (0.49) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| SCHEMBL3317227 | 0.82 | GAA (0.56) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| SCHEMBL15168 | 0.82 | GAA (0.61) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL19516242 | 0.81 | GAA (0.59) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| SCHEMBL13302638 | 0.81 | GAA (0.54) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| SCHEMBL1532183 | 0.81 | GAA (0.54) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| SCHEMBL9486189 | 0.79 | GAA (0.57) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| SCHEMBL9276769 | 0.79 | GAA (0.57) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| Bicarbonate SCHEMBL600121 | 0.79 | GAA (0.57) | GAABCL9CTNNB1ALDH1A1MAPK1 | |
| Benzene SCHEMBL28222061 | 0.79 | GAA (0.57) | GAABCL9CTNNB1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4071584-A | Hydroxyphenylthiophosphoranylidene organophosphorus compounds | MONSANTO COMPANY (US) | 1978-01-31 | — | — | US | claimed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3788049-B1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-02-23 | — | — | US | disclosed |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-11-04 | — | — | US | disclosed |
| EP-0216860-B1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS | SUMMERTON, James (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5034506-A | Polymers for the determination of genetic sequences and viral diseases | ANTI-GENE DEVELOPMENT GROUP (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0216860-A4 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. | SUMMERTON JAMES (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0215942-A4 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. | SUMMERTON JAMES | 1988-08-23 | — | — | EP | disclosed |
| EP-0216860-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. | SUMMERTON JAMES (US) | 1987-04-08 | — | — | EP | disclosed |
| EP-0215942-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. | SUMMERTON JAMES | 1987-04-01 | — | — | EP | disclosed |
| WO-1986005519-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| WO-1986005518-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| US-4108949-A | 6-Hydroxy (alkoxy) phenylthiomethylene di(organophosphorus) compounds and process for making same | MONSANTO COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4071584-A | Hydroxyphenylthiophosphoranylidene organophosphorus compounds | MONSANTO COMPANY (US) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | GAA 1238/4885BCL9 271/4885CTNNB1 1632/4885 |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | GAA 1806/4885BCL9 582/4885CTNNB1 3382/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | GAA 905/4885BCL9 83/4885CTNNB1 1542/4885 |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | GAA 1806/4885BCL9 582/4885CTNNB1 3382/4885 |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | GAA 1806/4885BCL9 582/4885CTNNB1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.